​

​

LightWorks Optics

​

LightWorks manufactures precision optical systems and components, including visible, infrared, and laser-based systems and subassemblies addressing the Defense, Aerospace, Industrial and Life Science markets. LightWorks Optical Systems, a subsidiary of II-VI, Inc., designs, manufactures, assembles and tests precision optical systems and components. Products have been deployed on military platforms such as submarines, tanks, missiles, fighter jets and UAV’s. LightWorks Optical Systems has grown over the years from a provider of specialty optical materials to a full service provider of optical components and optical systems. Expanding from its military based optical products to space, aerospace telescopes to life science applications in cataract surgery, DNA sequencing modules and commercial applications and products in lithography and telecommunications. II-VI Incorporated, is a global leader in engineered materials and optoelectronic components, is a vertically-integrated manufacturing company that creates and markets products for diversified markets including industrial manufacturing, military and aerospace, high-power electronics and telecommunications, and thermoelectronics applications. Headquartered in Saxonburg, Pennsylvania, with manufacturing, sales, and distribution facilities worldwide, the Company produces numerous crystalline compounds including zinc selenide for infrared laser optics, silicon carbide for high-power electronic and microwave applications, and bismuth telluride for thermoelectric coolers.

 

 

St. Jude Medical

​

St. Jude Medical (SJM) is a medical device company focused on providing products and services to physicians to manage chronic cardiovascular disease, vascular and chronic pain management through neurostimulation. SJM is a true “global” device company with 21 principal operating and manufacturing facilities worldwide, 100-plus countries where its products are sold, 49 percent of net sales in 2015 were international, and 47 percent of employees are based outside North America. With over $5B in worldwide sales, 46% of revenues from Cardiac Rhythm Management, and 44% from Cardiovascular and Atrial Fibrillation Management. SJM, is a global leader in Heart Failure Management including Cardiac Re-Synchronization Therapy; Cardiac Rhythm Management including implantable pacemakers and implantable cardioverter defibrillators (ICDs); Electrophysiology; Structural Heart; Vascular and Neuromodulation. Products and technologies include: single and dual chamber ICDs, single and dual chamber pacemakers, remote monitoring and programing devices/technology, delivery (defibrillation and pacing leads) products; quadripolar pacemakers and defibrillators; mapping, visualization and therapy electrophysiology catheters and technologies; structural heart occluders, mechanical and tissue heart valves; peripheral vascular embolization and intravascular diagnostic and imaging devices and stimulation products for spinal cord (chronic pain) deep brain (Parkinson’s and tremors), radiofrequency therapy (minimally invasive pain management). All products are supported by global clinical education and training curriculum and disease state management programs.
 

 

​

Edwards Lifesciences

​

Edwards Lifesciences is a $2B global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. With manufacturing operations in the United States, Puerto Rico, the Dominican Republic, Switzerland and Singapore, and global sales, clinical support and distribution in virtually every major country worldwide, Edwards collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives with heart valve and critical care technologies and products. Dedicated to improving the lives of patients with structural heart disease, transformational heart valve technology began in 1960 with the first commercially available heart valve.. Offerings include tissue replacement heart valves and repair products, as well as transcatheter heart valves for those patients considered at high or greater risk for conventional valve replacement. Edwards’ leadership in transcatheter heart valve replacement includes a commitment to meaningful innovation, rigorous scientific study, extensive clinician training and education, and significant investment in new applications of the technology. Edwards also offers market-leading technologies that facilitate on-pump cardiac surgery procedures through smaller incisions. Edwards’ minimally invasive valve surgery solutions are comprised of soft tissue retractors, venous and arterial cannulae, aortic occlusion, venting, and coronary sinus catheters. Starting with the development of Swan-Ganz advanced hemodynamic monitoring devices for measuring cardiovascular performance in high-risk surgical and critically ill patients, Edwards continues to evolve to less-invasive and noninvasive devices to provide valuable hemodynamic insight for an expanded patient population. Edwards has continued to advance hemodynamic monitoring platforms to enable proactive clinical decisions for surgical, anesthesia and critical care clinicians. Edwards is focused on helping clinicians enhance knowledge and standardize practice to improve the quality and efficiency of care. Edwards provides evidence-based programs such as Enhanced Surgical Recovery Program that support the implementation and compliance to protocolized care pathways in the OR and ICU.
 

​

​

IBM -Wilkerson Group

​

IBM Corp and its Global Business Consulting Group bought The Wilkerson Group, a consultancy that predicts trends in the pharmaceutical and medical products industry and devises strategies to leverage assets for growth. TWG has over 25 years of experience advising key stakeholders in the healthcare industry. Its clients include the major international pharmaceutical, biotechnology, supply, device and diagnostic companies. Founded in 1968, it has 100 employees based in New York and London. With the addition of TWG, IBM’s pharmaceutical and healthcare industry consulting offerings now range from strategic development to business process re-engineering and solutions implementation. Wilkerson’s grasp of the pharmaceutical, device and diagnostic industry, coupled with IBM’s technology solutions expertise, gives clients an unrivaled tool to win. Clients now have the full spectrum of services from one fully accountable global company. The acquisition of TWG, provides a combination of management consulting with information management and technology making IBM the unmatched leader in providing end-to-end solutions to the industry. Rapidly rising healthcare costs and increasingly complex interrelationships of pharmaceutical companies, hospitals, HMOs, individual country health systems, employers, insurance companies and individuals have made managing the healthcare system a critical imperative. Effective management is possible only with timely, accurate and complete information that can be easily accessed and immediately shared among the myriad players — a core IBM competency. TWG has more than 25 years of experience advising key stakeholders in the healthcare industry. It is recognized as a leader in anticipating emerging trends and devising strategies to leverage assets for growth. Its client base includes the major international pharmaceutical, biotechnology, supply, device and diagnostic companies and specialty for-profit service providers. The company was founded in 1968 and has some 100 employees in New York and London.
 

​

Bergen Brunswig

​

Bergen Brunswig Corporation at the time was a leading supplier of pharmaceuticals, medical- surgical supplies and specialty health-care products as well as information management solutions and consulting services. The company produces annual revenues of more than $22 billion. The company’s medical-supply subsidiary Bergen Brunswig Medical Corporation (BBMC) served health-care providers from 29 distribution centers across the country. BBMC produced annual revenues of approximately $870 million in medical devices and supply business to acute care, physician office, laboratories, surgical centers and long term care facilities. As a result of acquisitions, Bergen Bruswig’s pharmaceutical business is now a part of AmeriSource Bergen and its medical supply division (BBMC) is now a part of Allegiance’s $5B medical supply organization. Through its subsidiaries, Allegiance Corporation ( www.allegiance.net ) is a leading manufacturer and distributor of health-care products and cost-management services needed by hospitals, laboratories and others in health care. The company manufactures many of the products it markets and distributes, while others come from health and medical companies around the world. Allegiance also provides integrated services such as clinical and productivity consulting, procedure-based supply packaging, just-in-time delivery and other services to help medical professionals control costs and improve quality in patient care. Allegiance is now a subsidiary of Cardinal Health, Inc. which today is a $331B manufacturer and distributor of supplies and healthcare solutions.

 

 

​